Monomethyl triazeno imidazole carboxamide
CAS: 3413-72-7
Ref. 3D-FM26098
2mg | 250,00 € | ||
5mg | 351,00 € | ||
10mg | 468,00 € | ||
25mg | 729,00 € | ||
50mg | 1.214,00 € |
Produktinformation
- MTIC3-methyl(triazenyl)imidazole-4-carboxamide5-(3-methyltriazen-1-yl)imidazole-4-carboxamide
- NSC 407347
- Imidazole-4(or 5)-carboxamide, 5(or 4)-(3-methyl-1-triazeno)-
- 1H-Imidazole-4-carboxamide, 5-(3-methyl-1-triazenyl)-
- 5-[2-(Methylimino)hydrazinyl]-1H-imidazole-4-carboxamide
- 1H-Imidazole-4-carboxamide, 5-[2-(methylimino)hydrazinyl]-
- Imidazole-4-carboxamide, 5-(3-methyl-1-triazeno)-
Monomethyl triazeno imidazole carboxamide (MTIC) is a drug that is used to treat cancer. It has been shown to inhibit the proliferation of tumor cells and induce apoptosis by inhibiting the expression of proteins, such as Bcl-2, which are involved in regulating mitochondrial membrane potential. MTIC has also been shown to inhibit protein synthesis and cell signaling pathways, such as the PI3K/Akt pathway. The use of MTIC for diagnosis purposes can be achieved using electrochemical impedance spectroscopy. A concentration-time curve can be obtained by incubating a biological sample with MTIC and measuring cell response using an impedance spectrophotometer. The clinical properties of MTIC include its ability to be administered orally or intravenously, have low toxicity, and inhibit the growth of tumor cells in vivo and in vitro.
Chemische Eigenschaften
Technische Anfrage zu: 3D-FM26098 Monomethyl triazeno imidazole carboxamide
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.